StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
MGXMetagenomi Therapeutics, Inc.
stockpulse.co.kr
Nasdaq
$0.8236▲ 0.54%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $31.0MShares out 37.6M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

8
  • 9.22Pre-market26.09.22 09:49filed
    8-KKey event#●●●#●●●

    Metagenomi Therapeutics, Inc.

    Metagenomi Therapeutics reported $120.7 million in cash as of the end of Q2 2026, providing an operational runway through Q4 2027. The company plans to submit an IND for its lead hemophilia A candidate, MGX-001, in Q4 2026 to initiate Phase 1/2 clinical trials.…more

    $0.8236+0.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.11After-hours26.09.12 08:51
    4Ownership

    Metagenomi Therapeutics, Inc.

    Insider Reid Laurence of Metagenomi Therapeutics, Inc. reported a change in beneficial ownership of securities as of September 9, 2026. This filing serves as a formal disclosure of insider stock activity via Form 4.…more

    $0.8236+0.54%vs prev close
    View filingShare
  • 9.10After-hours26.09.11 05:05
    SCHEDULE 13GOwnership

    Metagenomi Therapeutics, Inc.

    A Schedule 13G filing has been submitted for Metagenomi Therapeutics, Inc. Thomas Brian C. has disclosed his beneficial ownership in the company, indicating a change in the holdings of a major shareholder.…more

    $0.8236+0.54%vs prev close
    View filingShare

7 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 10.13Pre-market26.10.13 21:00
    #●●●#●●●

    Metagenomi to Participate in Chardan Healthcare Conference

    Metagenomi Therapeutics will participate in a panel discussion at the Chardan 10th Annual Healthcare Conference to discuss its genome editing platforms. This event participation is a standard corporate update and does not carry immediate material impact on the stock.…more

    $0.8236+0.54%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 9.1Pre-market26.09.01 21:00

    ●●●●●●●● ●●●●● ●●●●●●

    Metagenomi Therapeutics announced that its CEO will participate in a fireside chat at the 21st Annual Wells Fargo Healthcare Conference. This event is a standard investor relations activity and does not provide immediate material impact on the stock.…more

    $0.8236+0.54%vs prev close
    Read sourceShareGlobeNewswire

1 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →